References
- Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9(Suppl. 4):14–27.
- Kyle RA, Gertz MA, Witzig TE, . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.
- Rosen LS, Gordon D, Kaminski M, . Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–1744.
- Melton LJ 3rd, Rajkumar SV, Khosla S, . Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004;19:25–30.
- Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011;17: 1278–1286.
- Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435–441.
- Dimopoulos M, Terpos E, Comenzo RL, . International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545–1556.
- Engelhardt M, Kleber M, Frydrychowicz A, . Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. Anticancer Res 2009;29:4745–4750.
- Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol 2011;29:1907–1915.
- Moulopoulos LA, Dimopoulos MA, Smith TL, . Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251–256.
- Stabler A, Baur A, Bartl R, . Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996;167: 1029–1036.
- Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118: 3205–3211.
- Delforge M, Terpos E, Richardson PG, . Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011;86:372–384.
- Terpos E, Christoulas D, Kastritis E, . Elevated levels of circulating activin-A correlate with features of advanced disease, extensive bone involvement and inferior survival in patients with multiple myeloma. Blood 2010;116(Suppl. 1): Abstract 2967.
- Morgan GJ, Davies FE, Gregory WM, . First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–1999.
- Rajkumar SV. Zoledronic acid in myeloma: MRC Myeloma IX. Lancet 2010;376:1965–1966.
- Gimsing P, Carlson K, Turesson I, . Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010;11:973–982.